Cost-effectiveness of Four Immunomodulatory Therapies for Relapsing-Remitting Multiple Sclerosis: A Markov Model Based on Long-term Clinical Data

BACKGROUND: Before the introduction of the immunomodulatory therapies for multiple sclerosis (MS), treatment options for MS consisted of symptomatic management (physical therapy and pharmacological treatment for symptom management). Symptomatic management for MS has been supplemented in the past dec...

Descripción completa

Detalles Bibliográficos
Autores principales: Bell, Christopher, Graham, Jonathan, Earnshaw, Stephanie, Oleen-Burkey, MerriKay, Castelli-Haley, Jane, Johnson, Kenneth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2007
Materias:
Formulary Management
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438176/
https://www.ncbi.nlm.nih.gov/pubmed/17407391
http://dx.doi.org/10.18553/jmcp.2007.13.3.245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438176/
https://www.ncbi.nlm.nih.gov/pubmed/17407391
http://dx.doi.org/10.18553/jmcp.2007.13.3.245

Ejemplares similares